Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

Core Insights - Altamira Therapeutics Ltd. will host its First Half 2024 Financial Results and Business Update Call on September 24, 2024, featuring remarks from CEO Thomas Meyer and COO Covadonga Pañeda, followed by a Q&A session [1] Company Overview - Altamira Therapeutics (Nasdaq: CYTO) specializes in nanoparticle-based technology for efficient RNA delivery to extrahepatic tissues, utilizing its OligoPhore™ and SemaPhore™ platforms [3] - The company is advancing two flagship siRNA programs: AM-401 targeting KRAS-driven cancer and AM-411 for rheumatoid arthritis, both currently in preclinical development beyond in vivo proof of concept [3] - Altamira's delivery platform is adaptable for mRNA and other RNA modalities, available for out-licensing to pharmaceutical and biotech companies [3] - The company holds a 49% stake in Bentrio®, an OTC nasal spray for allergic rhinitis, and is exploring partnerships or divestments for its inner ear legacy assets [3] - Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with primary operations in Basel, Switzerland [3]